Latest Conference Articles

The ELEVATE trial found combining elacestrant with everolimus or ribociclib is safe and effective for ER+/HER2- metastatic breast cancer.

Interim results reveal promising efficacy and safety of sacituzumab govitecan and pembrolizumab for muscle-invasive bladder cancer, enabling bladder preservation.

UGN-102 shows promising results in treating recurrent low-grade, intermediate-risk bladder cancer, with high response rates and manageable side effects.

Interim results reveal padeliporfin VTP therapy as a promising, safe treatment for low-grade upper tract urothelial cancer, preserving kidney function.

Combination therapy with BPd shows significant progression-free survival benefits in relapsed/refractory multiple myeloma patients with high-risk cytogenetic abnormalities.

A recent study reveals rising early-onset colorectal cancer rates, highlighting disparities and the need for improved screening and early detection strategies.

Nivolumab and relatlimab show promising intracranial activity in melanoma brain metastases, highlighting potential for further research in resistant cases.

Massimo Cristofanilli, MD, discusses the role of cell-free DNA in breast cancer.

Zipalertinib shows promising efficacy and safety for advanced NSCLC with EGFR exon 20 mutations, offering a much-needed oral treatment option.

A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors after initial treatment failure.

New findings reveal RP1 combined with nivolumab enhances response rates in advanced melanoma, especially with deep tumor injections, showing promising safety and efficacy.

A groundbreaking study reveals rusfertide's potential to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient quality of life.

Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative metastatic breast cancer patients post-CDK4/6 therapy.

A novel bispecific antibody, BNT327/PM8002, shows promising efficacy in treating unresectable mesothelioma, combining well with chemotherapy for durable responses.

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable vulvar cancer.

A novel combination therapy shows promise for advanced lung cancer patients resistant to standard treatments, offering hope for improved survival rates.

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple myeloma.

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a manageable safety profile.

In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual Meeting.

Higher pretreatment HER2 amplicon mRNA and HER2 protein levels predicted improved time to next treatment with T-DXd in metastatic breast cancer. Conversely, higher TOPO1 protein correlated with worse outcomes.

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and progression-free survival in recent clinical trials.

Adding cobolimab to dostarlimab as neoadjuvant treatment for high-risk resectable melanoma improved major pathological response rates and was tolerable.

Undetectable ctDNA at cycle 6 strongly predicts reduced progression/death risk in locally advanced cervical cancer patients treated with durvalumab/CRT or CRT alone.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

A single cilta-cel infusion led to 33% of heavily pretreated relapsed/refractory multiple myeloma patients remaining progression-free at 5+ years.

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.

Fruquintinib with chemotherapy and PD-1 blockade showed promising efficacy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.